Home » AGEB Journal » Issues » Volume 65" » Fasc.2 - Symposium » Article details

Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium

Journal Volume 65 - 2002
Issue Fasc.2 - Symposium
Author(s) J. B. Wong, F. Nevens
Full article
Full Article
VIEW FREE PDF
(1) Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA ; (2) Department of Medicine, Division of Hepatology, Catholic University Hospitals, Leuven, Belgium.

Initial therapy with peginterferon alfa-2b and rib- avirin results in a higher sustained virological response but is more expensive than interferon alfa-2b and rib- avirin. The objective of the analysis was to examine the cost- effectiveness of peginterferon alfa-2b combination therapy versus interferon alfa-2b combination therapy for treatment naïve chronic hepatitis C patients in Belgium.

© Acta Gastro-Enterologica Belgica.